Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Meenu Mehta; Deeksha; Devesh Tewari; Gaurav Gupta; Rajendra Awasthi; Harjeet Singh; Parijat Pandey; Dinesh Kumar Chellappan; Ridhima Wadhwa; Trudi Collet; Philip M. Hansbro; S. Rajesh Kumar; Lakshmi Thangavelu; Poonam Negi; Kamal Dua; Saurabh Satija

doi:10.1016/j.cbi.2019.05.028

Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Meenu Mehta
, Deeksha
, Devesh Tewari
, Gaurav Gupta
, Rajendra Awasthi
, Harjeet Singh
, Parijat Pandey
, Dinesh Kumar Chellappan
, Ridhima Wadhwa
, Trudi Collet
, Philip M. Hansbro
, S. Rajesh Kumar
, Lakshmi Thangavelu
, Poonam Negi
, Kamal Dua
, Saurabh Satija

Lovely Professional University
Suresh Gyan Vihar University
Amity University, Noida
Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa Rigpa and Homoeopathy
Baba Mastnath University
International Medical University
South Asian University
Queensland University of Technology
Centenary Institute
University of Technology Sydney
University of Newcastle
Saveetha Institute of Medical and Technical Sciences (Deemed to be University)
Shoolini University of Biotechnology and Management Sciences

Research output: Contribution to journal › Review article › peer-review

375 Scopus citations

Abstract

Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

Original language	English
Pages (from-to)	206-215
Number of pages	10
Journal	Chemico-Biological Interactions
Volume	308
DOIs	https://doi.org/10.1016/j.cbi.2019.05.028
State	Published - 1 Aug 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Nano-drug delivery
Novel approaches
Oligonucleotides
Respiratory diseases
miRNA
siRNA

Access to Document

10.1016/j.cbi.2019.05.028

Cite this

Mehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., Hansbro, P. M., Kumar, S. R., Thangavelu, L., Negi, P., Dua, K., & Satija, S. (2019). Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chemico-Biological Interactions, 308, 206-215. https://doi.org/10.1016/j.cbi.2019.05.028

@article{9204e2cffb3345cea982c112cc83f4df,

title = "Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases",

abstract = "Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.",

keywords = "Nano-drug delivery, Novel approaches, Oligonucleotides, Respiratory diseases, miRNA, siRNA",

author = "Meenu Mehta and Deeksha and Devesh Tewari and Gaurav Gupta and Rajendra Awasthi and Harjeet Singh and Parijat Pandey and Chellappan, \{Dinesh Kumar\} and Ridhima Wadhwa and Trudi Collet and Hansbro, \{Philip M.\} and Kumar, \{S. Rajesh\} and Lakshmi Thangavelu and Poonam Negi and Kamal Dua and Saurabh Satija",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = aug,

day = "1",

doi = "10.1016/j.cbi.2019.05.028",

language = "English",

volume = "308",

pages = "206--215",

journal = "Chemico-Biological Interactions",

issn = "0009-2797",

publisher = "Elsevier Ireland Ltd",

}

Mehta, M, Deeksha, Tewari, D, Gupta, G, Awasthi, R, Singh, H, Pandey, P, Chellappan, DK, Wadhwa, R, Collet, T, Hansbro, PM, Kumar, SR, Thangavelu, L, Negi, P, Dua, K & Satija, S 2019, 'Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases', Chemico-Biological Interactions, vol. 308, pp. 206-215. https://doi.org/10.1016/j.cbi.2019.05.028

TY - JOUR

T1 - Oligonucleotide therapy

T2 - An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

AU - Mehta, Meenu

AU - Deeksha,

AU - Tewari, Devesh

AU - Gupta, Gaurav

AU - Awasthi, Rajendra

AU - Singh, Harjeet

AU - Pandey, Parijat

AU - Chellappan, Dinesh Kumar

AU - Wadhwa, Ridhima

AU - Collet, Trudi

AU - Hansbro, Philip M.

AU - Kumar, S. Rajesh

AU - Thangavelu, Lakshmi

AU - Negi, Poonam

AU - Dua, Kamal

AU - Satija, Saurabh

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

AB - Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

KW - Nano-drug delivery

KW - Novel approaches

KW - Oligonucleotides

KW - Respiratory diseases

KW - miRNA

KW - siRNA

UR - https://www.scopus.com/pages/publications/85066284380

U2 - 10.1016/j.cbi.2019.05.028

DO - 10.1016/j.cbi.2019.05.028

M3 - Review article

C2 - 31136735

AN - SCOPUS:85066284380

SN - 0009-2797

VL - 308

SP - 206

EP - 215

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

ER -

Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this